Document is current

Article History

Received: 6 February 2026

Accepted: 7 April 2026

First Online: 18 April 2026

Declarations

:

: Dr José Manuel Carrascosa has served as principal investigator, scientific investigator, invited speaker, advisor and/or member of steering committees for Gebro, Nordic Pharma, Leo Pharma, AbbVie, Janssen, Novartis, Almirall, UCB, Lilly, Sandoz, Boehringer Ingelheim, Pfizer, Galderma and Bristol Myers Squibb, receiving grants and/or other compensation. Dr José Manuel Carrascosa is an Editorial Board member of Dermatology and Therapy. Dr José Manuel Carrascosa was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Dr Álvaro González-Cantero has served as a consultant for AbbVie, Apogee, Innovaderm, Organon, Janssen, Novartis, Lilly, Bristol Myers Squibb, Almirall, Boehringer Ingelheim, Amgen, Cerave, L'Oréal, Celgene and Leo Pharma, receiving grants and/or other compensation. Dr Ana Gutiérrez has received research support, congress sponsorship and/or personal fees as a speaker or consultant from AbbVie, Janssen, Lilly, FAES, Ferring, Adacyte, Takeda, Pfizer, Galápagos, Sandoz, Alfasigma, Falk and Fresenius Kabi. Dr Anna López Ferrer has received institutional research support, consultancy fees, and speaker honoraria from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, J&J Innovative Medicine, Leo Pharma, Lilly, Novartis, Takeda and UCB. Dr Anna López Ferrer is an Editorial Board member of Dermatology and Therapy . Dr Anna López Ferrer was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Dr Antonio Martorell has received institutional research support, consultancy fees, and speaker honoraria from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, J&J Innovative Medicine, Leo Pharma, Lilly, Novartis, Incyte, Sanofi, Pfizer and UCB. Dr Antonio Olveira has provided advisory services for Madrigal, Novartis, Amgen and Boehringer, and has given presentations for Novo Nordisk and Novartis. Dr Ofelia Baniandrés has participated as a consultant or speaker in events sponsored by J&J Innovative Medicine, AbbVie, Novartis, Lilly, Leo Pharma, Amgen, Boehringer Ingelheim, UCB, Bristol Myers Squibb and Almirall. Dr Pablo de la Cueva has acted as an advisor, investigator and/or speaker for the following pharmaceutical companies: AbbVie, Almirall, Astellas, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo Pharma, Lilly, MSD, Novartis, Pfizer, Sandoz, Sanofi and UCB. Dr Raquel Rivera has served as an advisor, speaker and investigator, and has received congress support from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, Janssen, Leo Pharma, Lilly, Novartis, Takeda and UCB. Dr Rubén Queiro has received institutional research support, project development funding, consultancy fees and speaker honoraria from AbbVie, Almirall, Amgen, J&J Innovative Medicine, Lilly, Novartis, Pfizer and UCB. The remaining authors declare no conflicts of interest.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.